Showing results (551-560 of 689) with videos related to

Sort By:
Pageof 69
ACS Nano|April 14, 2022
Optical Nanosensor for Intracellular and Intracranial Detection of Amyloid-BetaMerav Antman-Passig, Eitan Wong, Georgia R Frost, et al.
The New England Journal of Medicine|November 15, 2011
Full coverage for preventive medications after myocardial infarctionNiteesh K Choudhry, Jerry Avorn, Robert J Glynn, et al.
Circulation|May 6, 2009
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomesJessica L Mega, Sandra L Close, Stephen D Wiviott, et al.
The New England Journal of Medicine|June 5, 1980
Nifedipine therapy for coronary-artery spasm. Experience in 127 patientsE Antman, J Muller, S Goldberg, et al.
European Heart Journal|February 18, 2015
Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†Michelle L O'Donoghue, Christian T Ruff, Robert P Giugliano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 1998
Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancerL T Vahdat, K Papadopoulos, C Balmaceda, et al.
Circulation|October 11, 2019
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 TrialBrian A Bergmark, Pieter W Kamphuisen, Stephen D Wiviott, et al.
Circulation|April 15, 2015
Workplace wellness recognition for optimizing workplace health: a presidential advisory from the American Heart AssociationGregg C Fonarow, Chris Calitz, Ross Arena, et al.
JAMA Cardiology|July 10, 2024
Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical TrialAndré Zimerman, Eugene Braunwald, Jan Steffel, et al.
American Heart Journal|May 29, 1999
Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results. The TIMI Study GroupC M Gibson, K A Ryan, M Kelley, et al.
Pageof 69